TG Therapeutics

Investor & Analyst Meeting
June 6, 2016

GENUINE
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + IBRUTINIB
PHASE 3 TRIAL IN HIGH-RISK CLL

UNITY CLL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA TGR-1202
PHASE 3 TRIAL IN CLL

TG Therapeutics

Opening Remarks

Objectives - Agenda

Topic	Presenter
Welcome / Introductions	TG Therapeutics Team
TGR-1202 Monotherapy and TG-1303 Integrated Analysis Review UNITY-CLL High Risk Testing	Anthony Mato, MD
GENUINE Review & Supporting Data Screening Protocol/ High Risk Testing Community Oncologist Perspective	Kathryn Kolibaba, MD
UNITY-DLBCL TG-1303 Experience	Matthew Lunning, DO
Wrap-Up Moderated Q&A	TG Therapeutics Team


TG Therapeutics
NK cell
ADCC cytotoxic granules
ADCC cytotoxic granules
BCR
CD19
SYK
PI3K delta
BTK
PKC-β
AKT
CARD11
MALT1
BCL-10
mTOR
NF-κB
CD20
IRAK4
MYD88
IRAK1
TRAF6
TLR/IL-1
GITR
Tumor-Specific T-Cell
PD-1
PD-L1
Malignant B-Cell
Snail
Suppression of growth signaling
BET Inhibitor
Ublituximab (TG-1101), TGR-1202, IRAK4, PD-L1, and GITR represent investigational products and/or targets. These products have not been approved by the FDA.
1. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma—treatment approaches in the molecular era. Nature Reviews Clinical Oncology. 2014;11:12-23.
2. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Frontiers in Bioscience. 2011;16:277.306.
3. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012 Mar 22;12(4):237-51. doi: 10.1038/nrc3237.

TG Therapeutics

Anthony R. Mato, MD

Director, Center for CLL
University of Pennsylvania

Long-term follow-up of the PI3Kδ inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab

Howard A. Burris III, MD[1,2], Ian W. Flinn, MD, PhD[1,2,], Matthew Lunning, DO[3], Julie Vose, MD[3], Nathan Fowler, MD[4], Loretta Nastoupil, MD[4], Susan O'Brien, MD[5], Marshall T. Schreeder, MD[6], Manish R. Patel, MD[2,7], Timothy S. Fenske, MD[8], Danielle M. Brander, MD[9], Tanya Siddiqi, MD[10], Christopher Flowers, MD[11], Jan A. Burger, MD[12], William G. Wierda, MD[12], John G Kuhn, PharmD[13], Peter Sportelli[14], Hari P. Miskin, MS[14], Michael S. Weiss[14] and Owen A. O'Connor, MD, PhD[15]

[1]Tennessee Oncology, PLLC, Nashville, TN; [2]Sarah Cannon Research Institute, Nashville, TN; [3]University of Nebraska Medical Center, Omaha, NE; [4]Department of Lymphoma, MD Anderson Cancer Center, Houston, TX; [5]University of California Irvine, Orange, CA; [6]Clearview Cancer Institute, Huntsville, AL; [7]Florida Cancer Specialists, Sarasota, FL; [8]Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI; [9]Duke University Medical Center, Durham, NC; [10]City of Hope National Medical Center, Duarte, CA; [11]Emory University/Winship Cancer Institute, Atlanta, GA; [12]Department of Leukemia, MD Anderson Cancer Center, Houston, TX [13]University of Texas Health Science Center at San Antonio, San Antonio, TX; [14]TG Therapeutics, Inc., New York, NY; [15]Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: Demographics

Evaluable for Safety (n)	165 (90 Single Agent, 75 Combo with UTX)	
Median Age, years (range)	65 (22 - 86)	
Male/Female	106/59	
Histology	**CLL**	43
	FL	42
	DLBCL	40
	MZL	11
	HL	11
	MCL	8
	SLL	3
	WM	3
	T-Cell	2
	HCL	1
	Richter's	1
Median ECOG	1	
Prior Therapies, median (range)	3 (0 - 14)	
Patients with ≥ 3 Prior Therapies (%)	94 (57%)	
Patients Refractory to Prior Therapy (%)	85 (52%)	

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: Safety

All Causality AE's Occurring in ≥ 10% of Patients (n = 165)

Adverse Event	All Grades		Grade 3/4	
	N	%	N	%
Diarrhea	78	47%	5	3%
Nausea	74	45%	2	1%
Fatigue	61	37%	5	3%
Vomiting	44	27%	0	0%
Neutropenia	34	21%	30	18%
Cough	32	19%	0	0%
Dyspnea	30	18%	6	4%
Dizziness	29	18%	0	0%
Headache	28	17%	2	1%
Pyrexia	26	16%	2	1%
Decreased appetite	26	16%	0	0%
Rash	26	16%	6	4%
Sinusitis	25	15%	2	1%
Anemia	24	15%	9	5%
Constipation	24	15%	1	1%
Insomnia	23	14%	0	0%
Hypokalemia	22	13%	5	3%
Back pain	20	12%	1	1%
Abdominal pain	18	11%	4	2%
Upper respiratory infection	18	11%	0	0%

<8% of patients discontinued due to a TGR-1202 related AEs

13% of patients had a TGR-1202 dose reduction

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: Safety

- Grade 3/4 AST/ALT increase was 3% (8% all grades), predominantly observed above the Phase 3 dose
- Grade 3/4 pneumonia occurred in 5% of patients (8% all grades); two events of pneumonitis (<1.5%) were reported
- Two cases of colitis (<1.5%) have been reported at doses exceeding the Phase 3 dose and did not appear to be time dependent (1000 mg and 1200 mg, at 4 mos. and 24 mos., respectively, after initiating therapy).

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: Efficacy

Duration on Study (n=165)



- Extended durations of exposure
  - 80 patients for 6+ cycles
  - 43 patients for 12+ cycles
  - 14 patients for 24+ cycles
  - Longest patients on daily TGR-1202 for 3+ years

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: Efficacy at Phase 3 Dose

Overall Response Rate At Phase 3 Dose

Patients Exposed to TGR-1202 at 800 Micro						
Type	**Pts (n)**	**CR (n)**	**PR (n)**	**ORR n (%)**	**SD (n)**	**PD (n)**
CLL/SLL	16	2	12	**14 (88%)**	2	0
DLBCL	7	1	3	4 (57%)	2	1
iNHL	17	3	6	9 (53%)	6	2

- CLL/SLL PR includes 1 patient with persistent lymphocytosis [on single agent TGR-1202]
- iNHL = FL & MZL

- A strong dose response was observed, with patients exposed to 800 mg of the micronized formulation achieving higher rates of response

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: CLL/SLL Efficacy

Patients Treated at "Higher Doses" of TGR-1202

Best Percent Change from Baseline in Disease Burden



Higher Doses: 1200 mg of the initial formulation, or ≥600 mg of the micronized formulation

Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: CONCLUSIONS

- Discontinuations due to AEs have been limited and AEs generally associated with PI3K delta inhibitors have been rare
- Safety profile supports additional multi-drug combinations
  - Ongoing ibrutinib, bendamustine, and pembrolizumab with additional triple therapy studies planned
  - Study in patients intolerant to kinase inhibitors currently underway

UNITY-CLL Phase 3 Trial

- Design, Endpoints, and Statistics agreed to via Special Protocol Assessment (SPA)
- Enrolling ~450 patients with treatment naïve and previously treated CLL
- Efficacy Endpoints: ORR, PFS
- Study Chair: John Gribben, MD, PhD

UNITY CLL

TG THERAPEUTICS

GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA TGR-1202

PHASE 3 TRIAL IN CLL



TGR-1202 + TG-1101: Ibrutinib Refractory Patients

Ibrutinib Refractory Patients treated with TGR-1202 + TG-1101

Cyto-genetics	# of Prior Lines	Prior Therapies	% SPD reduction	ORR	Status
11q	4	1. R-Benda 2. Ofatumumab 3. Ibrutinib 4. Ibrutinib	-100%	PR	On Study
17p	2	1. R-Fludarabine 2. Ibrutinib	-37%	SD	Off (PD)
17p, p53	2	1. Ibrutinib 2. Bendamustine & CAR T-cell	-55%	PD	Off (PD)
No del	5	1. FCR 2. R-Benda 3. FCR 4. Campath+R 5. Ibrutinib	+25%	PD	Off (PD)

- All patients were treated with 800 mg of TGR-1202 in combination with ublituximab

Burris et al, ASCO 2016

Prevalence of High Risk Markers

Baseline mutational status of relasped/refractory CLL patients in clinical studies

	Idelalisib-Rituxan Phase III Trial (N=220)[5,6]	RESONATE (N=391)[7]	French CLL Intergroup ICLL01 (N=55)[8]	Ublituximab-Ibrutinib Phase II study (N=39)[9*]
17p del	26%	32%	27%	30%
p53 mut	18%	N/R	31%	5%
11q del	32%	31%	33%	28%

**Based on prior FISH in patient history*

- Due to overlapping features, it is estimated that over 50% of relapsed/refractory patients may have high-risk cytogenetics

Ibrutinib is not the entire solution!

Phase 3 Ibrutinib vs. Ofatumumab



- 32% of patients had 17p deletion

Ibrutinib prescribing information

High-Risk Patients Exhibit Poorer PFS



Byrd et al, NEJM 2013

High Incidence of Ibrutinib Discontinuations

Figure. Cumulative Incidence of Discontinuation of Ibrutinib Therapy



Cumulative Incidence Estimates, % (95% CI)

	At 12 mo	At 18 mo
CLL progression	0.3 (0-1.0)	2.4 (0.3-4.6)
RT	4.5 (2.0-7.0)	6.5 (3.3-9.6)
Other event	13.5 (9.5-17.6)	15.6 (11.1-20.0)

Maddocks et al JAMA Oncology 2015

TG Therapeutics

Take Home Summary

- High Risk CLL much more common than you think
- Most patients with relapsed CLL are suitable for novel agents, however outcomes for patients with high-risk features continue to be inferior
- Combination biologic therapy will likely lead to improved outcomes for patients with relapsed CLL

Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy

Anthony R. Mato, MD
Center for CLL
University of Pennsylvania

UNIVERSITY OF PENNSYLVANIA
Abramson Cancer Center

TG Therapeutics

Toxicity as Reason for Discontinuation

"Kinase Inhibitor Intolerant" Patients

5 Most Common Toxicities as a Reason for Discontinuation	
Ibrutinib (N=66)	**Idelalisib (N=18)**
Atrial fibrillation 20%	Pneumonitis 33%
Infection 12%	Colitis 28%
Hematologic 9%	Rash 17%
Bleeding 9%	Transaminitis 11%
Pneumonitis 8%	Infection 6%

Mato et al, ASH 2015

TG Therapeutics

Q & A Session

TG-1101 + Ibrutinib, Screening Protocol and Testing Relapsed High-Risk CLL

Kathryn Kolibaba, MD

Compass Oncology, Vancouver, WA; US Oncology Research, The Woodlands, TX

Can Ublituximab Improve Ibrutinib?

UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB ACHIEVES 95% ORR IN PATIENTS WITH HIGH-RISK RELAPSED/REFRACTORY CLL

Jeff Sharman[1,2], Charles M. Farber[3], Daruka Mahadevan[4], Marshall T. Schreeder[5], Heather D. Brooks[6,2], Kathryn S. Kolibaba[7,2], Suzanne Fanning[8,2], Leonard Klein[9,2], Daniel R. Greenwald[10,2], Peter Sportelli[11], Hari P. Miskin[11], Michael S. Weiss[11], John M. Burke[12,2]

[1]Willamette Valley Cancer Institute, Springfield, OR; [2]US Oncology Research, The Woodlands, TX; [3]Carol G. Simon Cancer Center, Morristown, NJ; [4]West Cancer Center/UTHSC, Memphis, TN; [5]Clearview Cancer Institute, Huntsville, AL; [6]Blue Ridge Cancer Care, Blacksburg, VA; [7]Compass Oncology, Vancouver, WA; [8]Greenville Health System Cancer Institute, Greenville, SC; [9]Illinois Cancer Specialists, Niles, IL; [10]Sansum Clinic, Santa Barbara, CA; [11]TG Therapeutics, Inc., New York, NY; [12]Rocky Mountain Cancer Centers, Aurora, CO

TG Therapeutics

Phase II: Ublituximab + Ibrutinib



- 900mg Ublituximab + 420mg Ibrutinib
- After cycle 6, all patients off study and remained on single agent ibrutinib per investigator discretion

Sharman, Burke et al, ICML 2015

Patient Characteristics – Phase II

Evaluable for Safety, (n)	44
Evaluable for Efficacy, † (n)	40
Median Age, years (range)	71 (39 – 86)
Male/Female	22/22
ECOG, median	1
Prior Regimens, median (range)	2 (1 – 7)
≥ 3 Prior Regimens	16 (36%)
Prior Anti-CD20 (rituximab, ofatumumab, obintuzumab)	41 (93%)
Refractory to anti-CD20	13 (33%)
Prior Alkylating Agent	28 (64%)
Prior Purine Analog	22 (50%)
High-risk (17p del, 11q del, p53 mutated)	21 (48%)

†4 patients not evaluable: 2 patients withdrew consent and 2 patients came off study prior to first disease assessment: 1 due to ibrutinib related AE (diarrhea); 1 due to multiple non-drug related AE's

Sharman, Burke et al, ICML 2015

Safety – Phase II

All Causality AE's in > 10% of Patients (n=44)		
Adverse Event	All Grades n (%)	Grade 3/4 n (%)
Infusion reaction	20 (45%)	3 (7%)
Diarrhea	16 (36%)	2 (5%)
Fatigue	13 (30%)	1 (2%)
Nausea	11 (25%)	-
Rash	10 (23%)	-
Pyrexia	8 (18%)	-
Arthralgia	7 (16%)	1 (2%)
Constipation	7 (16%)	-
Cough	7 (16%)	-
Muscle Spasms	7 (16%)	-
Peripheral Edema	7 (16%)	-
Upper Respiratory Tract Infection	7 (16%)	-
Dizziness	6 (14%)	-
Anemia	5 (11%)	5 (11%)
Contusion	5 (11%)	-
Headache	5 (11%)	-
Myalgia	5 (11%)	-
Neutropenia	5 (11%)	5 (11%)
Thrombocytopenia	5 (11%)	2 (5%)

Sharman, Burke et al, ICML 2015

Phase II Efficacy: Lymphocytosis

Absolute Lymphocytes in CLL Patients by Month on Treatment

Median, Interquartile Range (25% - 75%)



- Median 75% decrease in ALC from baseline by the end of Cycle 3
- 70% of CLL patients had ALC in normal range (<4000/uL) within 6 cycles of therapy

Sharman, Burke et al, ICML 2015

Phase II Efficacy: Nodal Reductions

Best Percent Change from Baseline in Nodal Size

Efficacy Assessed at Week 8 and Week 20 Only



*Detection of new lesion met iwCLL criteria for PD

- 37/40 (93%) achieved > 50% reduction in nodal size

Sharman, Burke et al, ICML 2015

Phase 2: Ublituximab + Ibrutinib
Best Overall Response Rate

Per study design, all patients were evaluated for efficacy at Month 2 and 5 only



25% of patients were <u>MRD negative or in CR</u> within 6 months of therapy

**2 patients had CR per iwCLL criteria without bone marrow confirmation*

Sharman, Burke et al, ICML 2015

The GENUINE Phase 3 Trial



- Design, Endpoints, and Statistics agreed to via Special Protocol Assessment (SPA)
- Enrolling ~330 patients with high-risk CLL

GENUINE
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB PLUS IBRUTINIB

- **Part 1**: ORR among first 200 patients—file for Accelerated Approval
- **Part 2**: PFS of all 330 patients—file for full approval
  - Part 1 to be analyzed following full enrollment of study

Previously Treated CLL Trial Opportunities



Overview

- Primary Objective
  - Identify high-risk genetic features (17p deletion, 11q deletion and/or TP53 mutation) of patients with previously treated Chronic Lymphocytic Leukemia (CLL).

- This screening protocol is for central testing of a blood sample for **potential enrollment on TG Therapeutics GENUINE trial**
  - If not high-risk, result can be used to satisfy FISH requirement for UNITY-CLL

Screening Protocol Benefits

- Results provide "best" treatment option = personalized approach to patient care
- Allows consideration of more than one treatment trial: GENUINE or UNITY- CLL
- Allows deferment of detailed discussion of GENUINE (or UNITY) until risk status is confirmed
- If not high risk, UNITY-CLL a perfect option and Screening Protocol fulfills 17p del testing requirement

TG Therapeutics

Matthew Lunning, DO

Assistant Professor, Division of Hematology
University of Nebraska Medical Center

Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results

Matthew Lunning, DO[1], Julie Vose, MD[1], Nathan Fowler, MD[2], Loretta Nastoupil, MD[2], Jan A. Burger, MD[2], William G. Wierda, MD[2], Marshall T. Schreeder, MD[3], Tanya Siddiqi, MD[4], Christopher R. Flowers, MD[5], Jonathon B. Cohen, MD[5], Susan Blumel, RN, BSN[1], Myra Miguel, RN[2], Emily K. Pauli, PharmD[3], Kathy Cutter, RN[3], Christine McCarthy[4], Ryan Handy, BS[5], Peter Sportelli[6], Hari P. Miskin, MS[6], Michael S. Weiss[6] and Susan O'Brien, MD[7]

[1]University of Nebraska Medical Center, Omaha, NE; [2]MD Anderson Cancer Center, Houston, TX; [3]Clearview Cancer Institute, Huntsville, AL; [4]City of Hope National Medical Center, Duarte, CA; [5]Emory University/Winship Cancer Institute, Atlanta, GA; [6]TG Therapeutics, Inc., New York, NY; [7]University of California Irvine, Orange, CA

TG-1101 (ublituximab) +TGR-1202 ("1303"): Demographics

Evaluable for Safety (n)	71	
Evaluable for Efficacy† (n)	58	
Median Age, years (range)	65 (26 – 86)	
Male/Female	47/24	
Histology	DLBCL	24
	CLL/SLL	19
	FL	19
	MZL	6
	MCL	2
	Richter's	1
ECOG, 0/1/2	20/47/4	
Prior Therapy Regimens, median (range)	3 (1 – 10)	
Patients with ≥ 3 Prior Therapies (%)	61%	
Prior RTX Based Therapies, median (range)	3 (1 – 7)	
Refractory to Prior Therapy, n (%)	41 (58%)	

†13 Patients not evaluable (9 too early, 2 non-related AE, 1 removed per investigator discretion, 1 for SAE, 1 ineligible)

Lunning et al, ASH 2015

TG-1101 (ublituximab) +TGR-1202 ("1303"): Safety

All Causality AE's Occurring in ≥ 10% of Patients (n = 71)

Adverse Event	All Grades		Grade 3/4	
	N	%	N	%
Nausea	33	46%	1	1%
Diarrhea	31	44%	2	3%
Fatigue	29	41%	2	3%
Neutropenia	21	30%	18	25%
Infusion related reaction	18	25%	1	1%
Vomiting	17	24%	-	-
Dyspnea	14	20%	2	3%
Back pain	13	18%	-	-
Dizziness	13	18%	-	-
Pyrexia	13	18%	2	3%
Decrease appetite	12	17%	-	-
Insomnia	12	17%	-	-
Sinusitis	11	15%	1	1%
Cough	10	14%	-	-
Anemia	9	13%	1	1%
Constipation	8	11%	-	-
Headache	8	11%	-	-
Vitamin D decrease	8	11%	-	-
Hypophosphatemia	7	10%	1	1%
Peripheral edema	7	10%	1	1%
Rash	7	10%	-	-

Of the 29 Gr 1/2 Diarrhea, only 11 were Gr.2, and no Gr. 4 events were observed

Data represents events occurring during entire duration on study (upwards of 22 mos.)

- 6 patients (8%) discontinued due to a TGR-1202 related AE
- Grade 3/4 AST/ALT increase was 3% (8% all grades)
- 7 patients (10%) had their TGR-1202 dose reduced; 2 diarrhea, 2 neutropenia, 1 nausea, 1 fatigue, 1 dizziness
- Colitis has not been reported to date

Lunning et al, ASH 2015

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: DLBCL Efficacy

Patients Treated at "Higher Doses" of TGR-1202

Best Percent Change from Baseline in Disease Burden



Burris et al, ASCO 2016

Integrated Analysis TGR-1202 Monotherapy and TGR-1202 + TG-1101: iNHL Efficacy

Patients Treated at "Higher Doses" of TGR-1202

Best Percent Change from Baseline in Disease Burden



Burris et al, ASCO 2016

TG-1101 (ublituximab) +TGR-1202: Efficacy

Patients with DLBCL

- 16 DLBCL patients evaluable:
- ORR: 33% (3/9) GCB, 0% (0/3) ABC, 50% (2/4) subtype unknown
- Notable activity has been observed particularly in patients with GCB DLBCL
- UNITY-DLBCL randomized study opening soon



Lunning et al, ASH 2015

DLBCL Case Study

- 74 yo female
- GCB Subtype
- Received R-CHOP frontline therapy
  - Relapsed within 1 year
- Received R-Gem/Ox
  - Relapsed within 6 months
- Started on TGR-1202 + TG-1101 clinical trial
  - Cycle 3: PR (54% reduction)
  - Cycle 6: PR (71% reduction)
  - Cycle 9: PR (71% reduction)
  - Cycle 12: PR (88% reduction)
- On study treatment for 13+ months

UNITY-DLBCL

- First patient enrolled!
- Phase 2b Randomized Trial of TG-1101 +TGR-1202
- Enrolling patients with previously treated DLBCL of all subtypes
- US Study Chair:
  Owen A. O'Connor, MD, PhD
- Ex-US Study Chair:
  Pier-Luigi Zinzani, MD, PhD

UNITY DLBCL
TG THERAPEUTICS
GLYCOENGINEERED UBLITUXIMAB + PI3K DELTA TGR-1202
PREVIOUSLY TREATED DLBCL PATIENTS



TG Therapeutics

Q & A Session